Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of YM178 in overactive bladder
2008-007087-42Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirabegron in overactive bladder (OAB) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Co-primary efficacy variables. Started Apr 2009; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2008-007087-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007087-42.